Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alpha Tau Medical

2.48
-0.1000-3.88%
Post-market: 2.500.0200+0.81%16:00 EDT
Volume:21.50K
Turnover:53.63K
Market Cap:174.54M
PE:-5.46
High:2.60
Open:2.60
Low:2.45
Close:2.58
Loading ...

BRIEF-Alpha Tau Receives FDA Approval To Initiate A Trial For Patients With Recurrent Glioblastoma

Reuters
·
02 Apr

Alpha Tau Medical Receives FDA Approval for Glioblastoma Trial

TIPRANKS
·
02 Apr

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients With Recurrent Glioblastoma

THOMSON REUTERS
·
02 Apr

Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma

GlobeNewswire
·
02 Apr

Q1 Virtual Investor Summit: On-Demand Presentations Now Live

ACCESS Newswire
·
19 Mar

Alpha Tau Medical Price Target Maintained With a $9.00/Share by HC Wainwright & Co.

Dow Jones
·
17 Mar

Alpha Tau Medical Faces Uncertain Future Amid Clinical Trial Challenges

TIPRANKS
·
14 Mar

Alpha Tau Medical Reports 2024 Earnings and Clinical Progress

TIPRANKS
·
14 Mar

March 2025 Penny Stocks To Consider For Growth

Simply Wall St.
·
04 Mar

Alpha Tau Medical to Showcase Alpha DaRT at March Investor Conferences

TIPRANKS
·
27 Feb

Alpha Tau to Participate in March Investor Conferences

GlobeNewswire
·
27 Feb

Alpha Tau Medical Gets Medical Device Single Audit Program Certification

MT Newswires Live
·
24 Feb

Alpha Tau Receives Medical Device Single Audit Program (MDSAP) Certification

GlobeNewswire
·
24 Feb

Alpha Tau Medical Gets FDA Approval to Expand DaRT Study in Pancreatic Cancer

MT Newswires Live
·
03 Feb

Alpha Tau Announces FDA Approval of Ide Supplement to Expand Pilot Trial of Alpha Dart® to Thirty Patients With Pancreatic Cancer in Two Cohorts, With Locally Advanced or Metastatic Disease

THOMSON REUTERS
·
03 Feb

Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease

GlobeNewswire
·
03 Feb

Alpha Tau Medical Reports Promising Interim Data and Regulatory Milestones in Cancer Trials

TIPRANKS
·
27 Jan

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to Be Shared at R&D Update Day

THOMSON REUTERS
·
27 Jan

Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day

GlobeNewswire
·
27 Jan

Alpha Tau Announces Upcoming Presentation of New Data at 2025 ASCO GI Symposium and at Company R&D Update Day

GlobeNewswire
·
18 Dec 2024